A study abstract presented at the European Hematology Association annual meeting found that, in a real-world setting, ruxolitinib resulted in prolonged survival among patients receiving the treatment following an allogeneic hematopoietic cell transplant.
Insight into the long-term safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients with myelofibrosis is suggesting positive implications of ruxolitinib treatment for these patients when given post transplant.
A study abstract presented at the European Hematology Association annual meeting found that, in a real-world setting, ruxolitinib resulted in prolonged survival among patients receiving the treatment following alloHCT, with 2-year overall survival (OS) improving significantly from 13.1% to 100%.
“Our real-world cohort indicates that the use of ruxolitinib has optimized outcomes of alloHCT. Especially after alloHCT, our results suggest a significant benefit of a personalized approach in ruxolitinib administration,” reflected the researchers, who noted that physicians are reluctant to refer patients for alloHCT since the emergence of Janus kinase 2 inhibitors despite efforts to expand alloHCT indications with improved patient stratification. “Given the safety of alloHCT, further studies are needed to guide this personalized approach.”
Throughout the study period, disease-free survival (DFS) was also superior among patients receiving ruxolitinib post-transplant; patients who received the JAK2 inhibitor after their alloHSCT had a 2-year DFS of 75% compared with 14.3% among patients who did not.
The study included 12 patients receiving alloHCT between 2000 and 2020, 7 of whom had primary myelofibrosis and 5 had secondary myelofibrosis. The majority (8 patients) received their transplant from a sibling donor and 4 received their transplant from an unrelated donor. All 12 patients received peripheral blood stem cells graft, either after myeloablative or reduced intensity conditioning regimens.
Among the patients, there was a 2-year treatment-related mortality rate of 34.6%.
“Ruxolitinib was administered in patients transplanted after 2015: before alloHCT in 6/6 patients, and after alloHCT in 4/6 (2 for relapsed disease, 1 for splenomegaly and thrombocytopenia despite involved field radiation therapy, and 1 for moderate chronic GVHD). Patients that received ruxolitinib post-transplant did not suffer from TRM,” explained the researchers.
Acute graft-versus-host disease (GVHD) was reported in 33% of patients and cumulative incidence of moderate chronic GVHD was 58%.
Reference
Sakellari I, Gavriilaki E, Mallouri D, et al. Improved survival in myelofibrosis patients receiving ruxolotinib post allogeneic hematopoietic cell transplantation. Presented at EHA 2021. Abstract EP1256.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More